← Back to Search

Acupuncture for Peripheral Neuropathy

N/A
Waitlist Available
Led By Ting Bao, MD, DABMA, MS
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Solid tumor survivors with no evidence of disease
Moderate to severe CIPN, defined by symptoms such as numbness, tingling, or pain ratings of 4 or greater on a 0-10 numeric rating scale (NRS)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks

Summary

This trial is testing whether real acupuncture can help reduce pain and improve symptoms for patients who have nerve damage from chemotherapy. Acupuncture has been studied for its potential benefits in reducing symptoms of nerve damage caused by chemotherapy, with some trials suggesting modest improvements.

Who is the study for?
This trial is for adults over 18 who have survived solid tumors with no current disease and suffer from moderate to severe nerve damage symptoms after chemotherapy. Participants should not have had any changes in their anti-neuropathy medication for three months and must speak English. Those with pacemakers or recent acupuncture treatments are excluded.
What is being tested?
The study aims to assess the effectiveness of real acupuncture versus placebo (sham) acupuncture or usual care in managing symptoms like numbness, tingling, or pain caused by nerve damage from chemotherapy.
What are the potential side effects?
Acupuncture may cause minor side effects such as bruising, bleeding at the needle sites, dizziness, fainting, or worsening of symptoms. The sham procedure might also lead to similar discomforts due to needle insertion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had cancer, but currently show no signs of the disease.
Select...
I experience significant numbness, tingling, or pain in my hands or feet.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
change in the proportion of patients with a CIPN severity

Side effects data

From 2013 Phase 1 & 2 trial • 104 Patients • NCT01305811
2%
Serious unexpected
2%
Pain on needling
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bi-Weekly Acupuncture
Wait List

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Acupuncture Treatment GroupExperimental Treatment2 Interventions
Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
Group II: Usual Care GroupActive Control2 Interventions
Twelve weeks of usual care.
Group III: Sham Acupuncture Treatment GroupPlacebo Group2 Interventions
Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acupuncture
2011
Completed Phase 3
~1240
questionnaires
2008
Completed Phase 2
~4390

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for peripheral neuropathy include medications like gabapentin and pregabalin, which work by modulating calcium channels to reduce nerve excitability and pain. Acupuncture, another treatment, stimulates specific points on the body to modulate pain and symptoms through neural, hormonal, and biochemical pathways, potentially altering brain activity and local tissue responses. Understanding these mechanisms is crucial for patients as it helps them make informed decisions about their treatment options, ensuring they choose therapies that best address their symptoms and improve their quality of life.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,969 Previous Clinical Trials
597,176 Total Patients Enrolled
Ting Bao, MD, DABMA, MSPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
546 Total Patients Enrolled

Media Library

Acupuncture Clinical Trial Eligibility Overview. Trial Name: NCT03183037 — N/A
Nerve Damage Research Study Groups: Sham Acupuncture Treatment Group, Usual Care Group, Acupuncture Treatment Group
Nerve Damage Clinical Trial 2023: Acupuncture Highlights & Side Effects. Trial Name: NCT03183037 — N/A
Acupuncture 2023 Treatment Timeline for Medical Study. Trial Name: NCT03183037 — N/A
~9 spots leftby Nov 2025